For more information, contact:

Nicole Fawcett, [email protected]




EMBARGOED for release at 11 a.m. ET May 28, 2018



Researchers identify a lncRNA that provides insight into a key driver of prostate cancer – and a potential target for future therapy


Newswise — ANN ARBOR, Michigan — The dark matter of the human genome may shed light on how the hormone androgen impacts prostate cancer.

Researchers at the University of Michigan Rogel Cancer Center identified a novel gene they named ARLNC1 that controls signals from the androgen receptor, a key player in prostate cancer. Knocking down this long non-coding RNA in mice led to cancer cell death, suggesting this may be a key target for future therapies. The study is published in Nature Genetics.

Current prostate cancer treatments aim to block the androgen receptor to stop cancer growth. But most patients become resistance to androgen-specific therapies, developing a challenging form of the disease called metastatic castration-resistant prostate cancer.

“The androgen receptor is an important target in prostate cancer. Understanding that target is important. This study identifies a feedback loop that we could potentially disrupt as an alternative to blocking the androgen receptor directly,” says study senior author Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology.

Chinnaiyan’s lab identified thousands of lncRNAs in a 2015 paper. Long non-coding RNAs are considered the dark matter of the genome because so little is known about them.

While searching for lncRNAs that might play a role in prostate cancer, the team discovered that ARLNC1 is elevated in prostate cancer relative to benign prostate tissue, which suggests a role in cancer development. And it was associated with androgen receptor signaling, which made it more intriguing. 

The researchers found that the androgen receptor actually induces ARLNC1 expression. Then ARLNC1 binds to the androgen receptor messenger RNA transcript. This stabilizes the level of androgen receptor, which then feeds back to sustain ARLNC1.

“At the end of the day, you’re creating or stabilizing more androgen receptor signaling in general and driving this oncogenic pathway forward. We’re envisioning a potential therapy against ARLNC1 in combination with therapy to block the androgen receptor – which would hit the target and also this positive feedback loop,” Chinnaiyan says.

When researchers blocked ARLNC1 in cell lines expressing androgen receptor, it led to cancer cell death and prevented tumor growth. In mouse models, elevating ARLNC1 caused large tumors to form. Knocking down ARLNC1 in mice caused tumors to shrink.

Researchers plan to continue studying the biology of ARLNC1 to understand how it’s involved in prostate cancer progression and androgen receptor signaling. 

“We want to further characterize the dark matter of the genome,” Chinnaiyan says. “There are a number of these lncRNAs that we don’t understand how they functionally work. Some of them will certainly be very useful as cancer biomarkers and we think a subset are important in biological processes.”

Additional authors: Yajia Zhang, Sethuramasundaram Pitchiaya, Marcin Cieslik, Yashar S. Niknafs, Jean C-Y. Tien, Yasuyuki Hosono, Matthew K. Iyer, Sahr Yazdani, Shruthi Subramaniam, Sudanshu K. Shukla, Xia Jiang, Lisha Wang, Tzu-Ying Liu, Michael Uhl, Alexander R. Gawronski, Yuanyuan Qiao, Lanbo Xiao, Saravana M. Dhanasekaran, Kristin M. Juckette, Lakshmi P. Kunju, Xuhong Cao, Utsav Patel, Mona Batish, Girish C. Shukla, Michelle T. Paulsen, Mats Ljungman, Hui Jiang, Rohit Mehra, Rolf Backofen, Cenk S. Sahinalp, Susan M. Freier, Andrew T. Watt, Shuling Guo, John T. Wei, Felix Y. Feng, Rohit Malik 

Funding: National Institutes of Health grants P50CA186786, U01 CA214170, DP5 OD012160; Prostate Cancer Foundation; Howard Hughes Medical Institute; American Cancer Society; University of Michigan Taubman Institute; U.S. Department of Defense grants W81XWH-13-1-0284, W81XWH-17-1-0134, W81XWH-16-1-0314; W81XWH-16-1-0195, W81XWH-14-1-0508, W81XWH-14-1-0509; AACR-Bayer Prostate Cancer Research Fellowship 16-4-044-PITC; German Research Foundation BA2168/11-1 SPP1738


Disclosure: The University of Michigan has filed a patent on lncRNAs as biomarkers of cancer and Chinnaiyan is named as an inventor. Chinnaiyan is a co-founder of LynxDx, which is developing lncRNA biomarkers.


Reference: Nature Genetics, doi: 10.1038/s41588-018-0120-1, published May 28, 2018



University of Michigan Rogel Cancer Center,

Michigan Health Lab,

Michigan Medicine Cancer AnswerLine, 800-865-1125


# # #